Posted by djmmm on July 10, 2003, at 14:06:00
In reply to Effexor metabolite in Phase III testing, posted by jrbecker on July 10, 2003, at 12:57:18
> It looks like some pharm company is trying to bring a new drug containing an active metabolite of Effexor to the market. Currently being called DVS-233 SR, it is in Phase III for depression.
>
> I'm not sure if this is Wyeth (Effexor's manuf.) or another company that's testing the drug. It could be one way Wyeth's plans to extend its share of the market once Effexor goes generic in 2007 (a la Lexapro succeeding Celexa, Focalin succeeding Ritalin). Or maybe Wyeth is leasing the metabolite out to another pharm company.
>
> Supposedly, anybody that has taken Effexor within 90 days is excluded from the study. Whether you have and you decide to share that information with them, well, that's up to you.
>
> Go to http://www.centerwatch.com and search by "DVS-233 " if you would like to participate, to see if there is a test site near you.
>
> The locations I was able to find were: Santa Monica, CA; Newport Beach, CA; Orange, CA; Wheat Ridge, CO; New Britain, CT; Winter Park, FL; St. Petersburg, FL; Chicago, IL; Okemos, MI; Omaha, NE; Moorestown, NJ; New York, NY; Havertown, PA; Dallas, TX; Austin, TX; Washington, DC
>
> http://www.centerwatch.com/search.asp?FreeText=off&qu=dvs-233
>
>I heard about this, it's desvenlafaxine (O-desmethylvenlafaxine) it is slightly more potent than the parent drug, and it's half life is about 10 hours compared to venlafaxine's 4 hour half-life. Now they can sell DSV233-SR as a once daily version of effexor (I'm assuming the "SR" part of the code designation is "slow-release")
poster:djmmm
thread:240601
URL: http://www.dr-bob.org/babble/20030708/msgs/240620.html